Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'

被引：3
|
作者：
Cai, Guoqi [1 ]
Peng, Xiaoqing [2 ]
机构：
[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China
[2] Anhui Med Univ, Affiliated Hosp 1, Dept Obstet & Gynaecol, Hefei 230032, Anhui, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 07期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1136/annrheumdis-2021-220904
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 45 条
  • [31] Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!) (vol 389, pg 505, 2016)
    Henao-Restrepo, A. M.
    Camacho, A.
    Longini, I. M.
    LANCET, 2017, 389 (10068): : 504 - 504
  • [32] Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan
    Hassanein, Mohamed
    Echtay, Akram Salim
    Malek, Rachid
    Omar, Mahomed
    Shaikh, Shehla Sajid
    Ekelund, Magnus
    Kaplan, Kadriye
    Kamaruddin, Nor Azmi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 135 : 218 - 226
  • [33] Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne M.
    Pan, Lili
    Liu, Weihong
    Zhao, Weigang
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1652 - 1660
  • [34] EFFICACY OF ADALIMUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INVESTIGATOR-INITIATED 12-WEEKS RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH A 12 WEEKS OPEN-LABEL EXTENSION PHASE
    Pedersen, S. J.
    Sorensen, I. J.
    Loft, A. G.
    Hindrup, J. S.
    Thamsborg, G.
    Asmussen, K.
    Kluger, E.
    Norregaard, J.
    Christensen, T. G.
    Jurik, A. G.
    Moller, J. M.
    Hasselquist, M.
    Skjodt, T.
    Mikkelsen, D.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 289 - 289
  • [35] Delivery effectiveness of and adherence to intermittent preventive treatment for malaria in pregnancy with dihydroartemisinin-piperaquine with or without targeted information transfer or sulfadoxine-pyrimethamine in western Kenya: a three-armed, pragmatic, open-label, cluster-randomised trial
    Barsosio, Hellen C.
    Webster, Jayne
    Omiti, Frederick
    K'Oloo, Alloys
    Odero, Isdorah A.
    Ojuok, Michael A.
    Odiwa, Dawn
    Omondi, Benson
    Okello, Elizabeth
    Dodd, James
    Taegtmeyer, Miriam
    Kuile, Feiko O. ter
    Lesosky, Maia
    Kariuki, Simon
    Hill, Jenny
    LANCET GLOBAL HEALTH, 2024, 12 (10): : e1660 - e1672
  • [36] Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole plus diethylcarbamazine plus ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
    Tavul, Livingstone
    Laman, Moses
    Howard, Cade
    Kotty, Bethuel
    Samuel, Anna
    Bjerum, Catherine
    O'Brian, Kobie
    Kumai, Steven
    Amuga, Matthew
    Lorry, Lina
    Kerry, Zebedee
    Kualawi, Melvin
    Karl, Stephan
    Makita, Leo
    John, Lucy N.
    Bieb, Sibauk
    Wangi, James
    Weil, Gary J.
    Goss, Charles W.
    Tisch, Daniel J.
    Pomat, William
    King, Christopher L.
    Robinson, Leanne J.
    PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (02):
  • [37] Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
    Davies, M. J.
    Gross, J. L.
    Ono, Y.
    Sasaki, T.
    Bantwal, G.
    Gall, M. A.
    Niemeyer, M.
    Seino, H.
    DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 922 - 930
  • [38] Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3,26 week, randomised, open-label, treat-to-target, non-inferiority trials
    Zinman, Bernard
    DeVries, J. Hans
    Bode, Bruce
    Russell-Jones, David
    Leiter, Lawrence A.
    Moses, Alan
    Johansen, Thue
    Rather, Robert
    LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (02): : 123 - 131
  • [39] Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
    Russell-Jones, David
    Babazono, Tetsuya
    Cailleteau, Roman
    Engberg, Susanne
    Irace, Concetta
    Kjaersgaard, Maiken Ina Siegismund
    Mathieu, Chantal
    Rosenstock, Julio
    Woo, Vincent
    Klonoff, David C.
    LANCET, 2023, 402 (10413): : 1636 - 1647
  • [40] Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial
    Hsiang, Michelle S.
    Ntuku, Henry
    Roberts, Kathryn W.
    Dufour, Mi-Suk Kang
    Whittemore, Brooke
    Tambo, Munyaradzi
    McCreesh, Patrick
    Medzihradsky, Oliver F.
    Prach, Lisa M.
    Siloka, Griffith
    Siame, Noel
    Gueye, Cara Smith
    Schrubbe, Leah
    Wu, Lindsey
    Scott, Valerie
    Tessema, Sofonias
    Greenhouse, Bryan
    Erlank, Erica
    Koekemoer, Lizette L.
    Sturrock, Hugh J. W.
    Mwilima, Agnes
    Katokele, Stark
    Uusiku, Petrina
    Bennett, Adam
    Smith, Jennifer L.
    Kleinschmidt, Immo
    Mumbengegwi, Davis
    Gosling, Roly
    LANCET, 2020, 395 (10233): : 1361 - 1373
12345